Features | Partner Sites | Information | LinkXpress
Sign In
FOCUS DIAGNOSTICS, INC.
RANDOX LABORATORIES
GLOBETECH PUBLISHING

Ceramides in Blood Predict Risk of Alzheimer's Disease

By Labmedica International staff writers
Posted on 31 Jul 2012
High levels of ceramides, a family of lipids, in the blood of a patient may be predictive of developing Alzheimer's disease.

Dr. Mielke PhD, from the Mayo Clinic (Rochester, MN, USA) and her team conducted a study to see whether blood levels of ceramides and sphingomyelins are associated with increased risk of Alzheimer's disease (AD). Previous studies found links between high serum ceramide levels and memory impairment and hippocampal volume loss.

Participants in a longitudinal, population-based study included healthy women 70 to 80 years of age, living in Baltimore, (Maryland, USA). None had dementia at baseline. The women were followed for up to six visits over nine years. Their blood was collected at baseline and at each subsequent visit. Out of 99 women, 27 (27.3%) developed incident dementia. Of these, 18 (66.7%) were diagnosed with probable Alzheimer's disease.

An increased risk of Alzheimer's disease was associated with higher baseline serum ceramides. However, higher levels of sphingomyelins were not linked to increased Alzheimer's disease risk. The team also noted that women in the middle tertile of serum ceramide levels had the highest risk for Alzheimer's versus those in the lowest tertile, with an intermediate increased risk seen among those in the highest tertile.

Michelle M. Mielke said, "The study is small—that's a limitation, and it was a preliminary study. However, given the small sample size, to have hazard ratios that are near 10 was quite striking and we didn't expect to see that at all," said Dr. Mielke. "Pretty much any marker is not going to be associated with a 10-fold risk, so yes, this does need to be replicated in another study, but it suggests to us that plasma or blood ceramide levels are associated with an increased risk of Alzheimer's disease," she said.

According to Valory Pavlik, PhD, of the Alzheimer's disease and memory disorders center at Baylor College of Medicine (Houston, TX, USA) the study findings are noteworthy. Identification of an accurate biomarker to predict Alzheimer's disease that can be obtained with a minimum of cost and inconvenience to a patient, could lead to model focused on preventing or delaying disease onset.

Related Links:
Mayo Clinic
Baylor College of Medicine



VIRCELL
DiagCor Bioscience
Sekisui Diagnostics
comments powered by Disqus
Life Technologies

Channels

Immunology

view channel
Image: The fluorescence-activated cell sorting FACSCanto II flow cytometer (Photo courtesy of BD Biosystems).

Flow Cytometry Detects Lymphoproliferative Disorders in Fluid Specimens

Immunophenotypic analysis of hematopoietic cell populations by flow cytometry has emerged as a useful ancillary study in the diagnostic evaluation of serous effusions and cerebrospinal fluids (CSFs).... Read more

Lab Tech.

view channel
Image: A technical breakthrough for DNA imaging has been achieved that should quicken diagnosis of diseases for which analysis of DNA from single-cells is critical, such as early stage cancers and various pre-natal conditions (Photo courtesy of McGill University and Génome Québec Innovation Center).

Breakthrough DNA Analysis Technology to Hasten Problem Diagnosis

Researchers have achieved a technical breakthrough that should result in speedier diagnosis of diseases for which analysis of DNA from single-cells is critical, such as early stage cancers and various... Read more

Industry News

view channel

Most IVD Sector Companies Look Outside the EU and USA for Growth

Kalorama Information (New York City, NY, USA) has now published the 9th edition of its biennial market research report “Worldwide Market for In Vitro Diagnostics,” revealing estimates from its survey of the in vitro diagnostics (IVD) industry – presenting the trends, technologies, customer needs, and major suppliers with... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.